Agilent Technologies Inc.
ABusiness Overview
ticker: A step: 01 generated: 2026-05-12 source: quick-research
Agilent Technologies (A) — Business Overview
Business Description
Agilent Technologies is a global leader in analytical laboratory instruments, consumables, software, and services used in life sciences, diagnostics, and applied chemical markets. Spun off from Hewlett-Packard in 1999, the company serves pharmaceutical, biotechnology, academic, food safety, environmental, and clinical customers in over 100 countries. Agilent's portfolio spans chromatography (LC/GC), mass spectrometry (LC/MS, GC/MS, ICP-MS), spectroscopy, genomics, and cell analysis — connected by a large installed base generating recurring consumable and service revenue.
Revenue Model
Agilent earns revenue through instrument capital sales (one-time), followed by recurring consumable (reagents, columns, supplies), service contract, and software subscription revenue. Recurring revenue (consumables + services + software) now represents approximately 50% of total revenue, providing earnings stability through instrument purchase cycles. The ACG (Agilent CrossLab Group) segment manages aftermarket services and software, delivering predictable high-margin revenue. The company has shifted emphasis toward services and diagnostics (clinical/companion diagnostics) to diversify from biopharma capital spending cycles.
Products & Services
- Liquid Chromatography (LC): Instruments and consumables for pharmaceutical quality control, drug development, and food safety
- Gas Chromatography (GC): Instruments for environmental, food, forensics, and petrochemical analysis
- Mass Spectrometry: LC/MS and GC/MS systems for proteomics, metabolomics, and drug metabolism
- ICP-MS/OES: Elemental analysis instruments for environmental, food, and semiconductor markets
- Cell Analysis (Seahorse XF): Metabolic profiling systems for biomedical research
- Companion Diagnostics: FDA-cleared clinical diagnostic tests (PD-L1 IHC 22C3 pharmDx for oncology); PathAI collaboration
- CrossLab Services: Instrument maintenance, calibration, training, and lab management services
- Software: OpenLab CDS (chromatography data system), MassHunter, SLIMS LIMS
Customer Base & Go-to-Market
Agilent serves over 300,000 customers globally, including 2,000+ biopharmaceutical companies, CROs, CMOs, academic research institutions, government labs, food and beverage manufacturers, environmental testing labs, and hospitals/clinical labs. Revenue is geographically balanced: Americas ~40%, Asia-Pacific ~33%, Europe ~27%. The company sells through a direct sales force supplemented by distributors in emerging markets.
Competitive Position
Agilent is the global leader in liquid chromatography and mass spectrometry, competing primarily with Waters Corporation, Thermo Fisher Scientific (in LC/MS and ICP), Shimadzu, and SCIEX. Its durable competitive advantages include deep customer integration through CrossLab service contracts, the largest installed base in LC/GC with high consumables attach rates, and a growing clinical diagnostics franchise that is less exposed to biopharma capex volatility. The "Ignite Transformation" operating model (launched 2024–2025) is improving operational efficiency and margin structure.
Key Facts
- Founded: 1999 (spun off from Hewlett-Packard)
- Headquarters: Santa Clara, California
- Employees: ~18,000
- Exchange: NYSE
- Sector / Industry: Healthcare / Life Sciences Tools & Services
- Market Cap: ~$22B
- Fiscal Year End: October 31
Financial Snapshot
ticker: A step: 04 generated: 2026-05-12 source: quick-research
Agilent Technologies (A) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $6.85B | $6.83B | $6.51B | -4.7% |
| Gross Margin | ~52.5% | ~50.7% | ~54.3% | +3.6pp |
| Operating Margin | ~20.2% | ~19.8% | ~22.9% | +3.1pp |
| Net Income | ~$1.49B | ~$1.21B | ~$1.29B | +6.6% |
| EPS (diluted) | ~$5.06 | $4.19 | ~$4.44 | +6% |
Note: Agilent fiscal year ends October 31. FY2023 revenue was flat YoY due to post-pandemic biopharma inventory destocking and slowing pharma capex. FY2024 decline reflects continued biopharma spending headwinds, partially offset by cost actions. Gross margin recovery in FY2024 reflects favorable mix (more services/consumables) and Ignite Transformation savings.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$1.55B |
| Free Cash Flow | ~$1.37B |
| Cash & Equivalents | ~$1.1B |
| Total Debt | ~$2.9B |
Key Ratios (approximate)
- P/E: ~17x (FY2024) | EV/EBITDA: ~14x | FCF Yield: ~6%
- Revenue Growth (FY2024): -4.7% | FCF Margin: ~21%
- Dividend Yield: ~1.0%
Growth Profile
Agilent's revenue declined in FY2023–FY2024 due to a severe biopharma inventory correction and reduced capital spending across pharmaceutical and biotech customers. FY2025 saw recovery with revenue of $6.95B (+6.7%), and management raised FY2026 guidance to $7.30B–$7.50B, implying continued recovery as biopharma destocking ends, order book-to-bill exceeds 1.0x, and the diagnostics segment (clinical diagnostics, companion diagnostics) accelerates. The Ignite Transformation program is driving structural margin improvement, with operating margins expected to expand toward 24–25% as revenue recovers.
Forward Estimates
- FY2025 (ended Oct 2025): Revenue $6.95B (actual); recovery year with margin expansion
- FY2026E Revenue: $7.30B–$7.50B (company guidance) — ~5–8% growth
- FY2026E EPS: Mid-to-high $5 range (consensus), with operating leverage from revenue recovery
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $A.